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Abstract Reducing the amount of Helicobacter pylori in
the stomach by selective bacterial–bacterial cell interaction
was sought as an effective and novel method for combating
the stomach pathogen. Lactobacillus reuteri DSM17648
was identified as a highly specific binding antagonist to H.
pylori among more than 700 wild-type strains of Lacto-
bacillus species. Applying a stringent screening procedure,
the strain DSM17648 was identified as selective binder to
H. pylori cells under in vivo gastric conditions. The strain
DSM17648 co-aggregates the pathogen in vivo and
in vitro. The specific co-aggregation occurs between Lact.
reuteri DSM17648 and different H. pylori strains and
serotypes, as well as H. heilmannii, but not with Cam-
pylobacter jejuni or other commensal oral and intestinal
bacteria. Lact. reuteri DSM17648 was shown in a proof-of-
concept single-blinded, randomized, placebo-controlled
pilot study to significantly reduce the load of H. pylori in
healthy yet infected adults. Reducing the amount of H.
pylori in the stomach by selective bacterial–bacterial cell
interaction might be an effective and novel method for
combating the stomach pathogen. Lact. reuteri DSM17648
might prove useful as an adhesion blocker in antibiotic-free
H. pylori therapies.
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Introduction
Helicobacter pylori is a recognized pathogen and carcin-
ogen causing gastritis, ulcers and gastric cancer. More than
50 % of the world population is infected with this stomach
bacterium [1, 2]. Severity of the clinical manifestations of
the infection is associated with bacterial load [3–5]. Cur-
rently, the only therapeutic option is eradication of the
pathogen by a combination of several antibiotics and a
proton-pump inhibitor (triple therapy; Maastricht IV/Flor-
ence Consensus Report) [6]. Eradication therapy is asso-
ciated with severe side effects and development of
antibiotic resistances [7]. Reducing the amount of H. pylori
in the stomach by selective bacterial–bacterial surface
interaction represents an alternative method for combating
the stomach pathogen. Specific co-aggregation has been
widely discussed as a means to return to homeostasis in
diseased states [8–10]. While H. pylori resides in the
mucus where it is present in its motile form, mucus is
constantly produced by the epithelium and shed into the
stomach lumen. This continuously releases planktonic H.
pylori cells into the stomach. The Lactobacillus strain
identified in this study specifically captures such H. pylori
cells. As spray-drying or freeze-drying procedures allow
the retention of binding activity, structures in the cell wall
unaffected by the drying procedures are supposed to be
responsible for the aggregation activity.
Previous papers describing the use of Lact. reuteri in H.
pylori-related clinical studies show a reduction in H.
pylori-associated urease activity by Lact. reuteri strain
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ATCC55730 [11]. Dore et al. [12] showed that the oral
application of Lact. reuteri strain DSM17938, when used in
combination with pantoprazole twice a day for 8 weeks,
resulted in significant reduction in the urease breath test.
Emara et al. [13] used a Lact. reuteri preparation (a mixture
of strains Lact. reuteri DSM17938 and Lact. reuteri ATCC
PTA6475 in combination with a triple therapy). The Lac-
tobacillus supplementation increased the Gastrointestinal
Symptom Rating Scale (GSRS) score significantly, but did
not improve the eradication rate.
The aim of the present study was to characterize the
binding activity of Lact. reuteri strain DSM17648 to H.
pylori in vitro and to determine the impact of 14 days of
oral intake of lyophilized Lact. reuteri DSM17648 cells
(non-viable) on H. pylori load in a single-blinded, placebo-
controlled study.
Materials and Methods
Microorganisms and Cultivation
Lactobacillus strains (strains from ORGANOBALANCE
GmbH, Berlin, Germany) were grown in Lactobacillus
MRS medium [14] at 37 C, and H. pylori DSM21031 and
Campylobacter jejuni DSM 4688T were grown in Brucella/
FBS broth (BD, Heidelberg, Germany, with 10 % (v/v)
fetal bovine serum, Biochrom, Berlin, Germany) at 37 C
in microaerobic atmosphere. Other Helicobacter species
were grown in Brucella/FBS broth containing additionally
0.75 % (v/v) Vitox supplement (Oxoid, Wesel, Germany)
[15].
The taxonomic identification of the Lactobacillus strains
to the species level relied on 16 S-rDNA sequence analysis
(sequencing done LCG Genomics, taxonomic classification
done by Nadicom, Karlsruhe, Germany) using the primers
27f (50-AGAGTTTGATCMTGGCTCAG-30) and 1492r
(50-ACGGYTACCTTGTTACGACTT-30) [16] and on
phenotypic characterization using the API 50 CH system
and apiwebTM software (bioMerieux, France). Bacterial
counts were determined from calibration curves of optical
density versus microscopic cell counts using a Neubauer
chamber (Carl Roth, Karlsruhe, Germany).
Chemicals and Enzymes
Sugars, sugar substitutes and inorganic chemicals were
reagent grade (Merck, Darmstadt; Carl Roth, Karlsruhe;
Germany), and proteases (protease from Streptomyces
griseus, proteinase K from Tritirachium album, trypsin
from bovine pancreas and pepsin from bovine pancreas)
were of the highest commercially available grade (Sigma,
Taufkirchen, Germany).
Screening for Co-aggregates
Co-aggregation was performed with stationary-phase cells
of lactobacilli (A600 = 4, in PBS) and H. pylori
(A600 = 2, in artificial gastric juice pH 4, 0.3 % (w/v)
pepsin, 0.5 % (w/v) sodium chloride [17]). Cells were
mixed and immediate flocculation was observed. Co-
aggregates could be observed visually as flocking struc-
tures, whereas no such structures were present in controls
of the single strains (see also Fig. 1). If no aggregates were
detected after 10 min, pairs were judged as non-co-
aggregating.
For some experiments, cells were stained separately using
either hexidium iodide (HI, 10 lg/mL) or carboxyfluores-
cein diacetate succinimidyl ester (CFDA-SE 1 lg/mL)
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. Excess dye was removed by exten-
sive washing with PBS. Equal amounts of cells were mixed
and vortexed for 10 s prior to phase-contrast and fluores-
cence microscopy [10].
Flow Cytometry
Lactobacillus cells (without staining) and H. pylori cells
stained with CFDA-SE were used for co-aggregation by
mixing suspensions of the strain DSM17648 and H. pylori
strain DSM21031T in a ratio of 1:1 (cell/cell) to a final
volume of 100 lL and subsequent shaking for 15 min. The
mixture was added to 990 lL 0.5 % (v/v) sodium chloride
(pH 4) in FACS tubes (BD, Heidelberg, Germany). A non-
co-aggregating Lactobacillus strain was used as a negative
control. Samples were analyzed using a flow cytometer
(FACSCalibur, BD, Heidelberg, Germany). Cell co-
aggregation was quantified by determining events with a
high fluorescence intensity ([5 9 102) via channel FL1-H
(Ex 488 nm, Em 530/30) [18, 19].
Scanning Electron Microscopy (SEM)
Cells were prepared as described above and re-suspended
in PBS. Co-aggregation was induced by mixing suspen-
sions of the strain DSM17648 and H. pylori strain
DSM21031T at a ratio of 1:1 (cell/cell). After 20-min
incubation at room temperature, the resulting co-aggregates
were pelleted by centrifugation (7,1509g, 1 min, Hettich
Mikro 22R, Tuttlingen, Germany). The supernatant was
carefully discarded, and co-aggregates were either frozen
in liquid nitrogen, freeze-dried and sputtered with palla-
dium (1,8009 picture) or fixed in 4 % glutaraldehyde,
dehydrated in graded ethanol solutions, dried in liquid CO2
and sputtered with palladium (11,0009 picture) before
SEM. SEM was done using a FEI Quanta 200 FEG Field
emission scanning electron microscope. Some images were
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colorized according to the bacillary or spiral shape to
facilitate viewing (eye of science Meckes and Ottawa GbR,
Reutlingen, Germany).
Sugar and pH Effects on Co-aggregation
Co-aggregation was tested in the presence of 25 mM
sucrose with known co-aggregating pairs. Analogous
simultaneous incubations were done testing lactose, glu-
cose, maltose, iso-maltose, fructose or sorbitol to detect
possible interference with the ability of the strain
DSM17648 to co-aggregate H. pylori. To evaluate the pH
dependency of co-aggregation, DSM17648 cells were re-
suspended in 0.1 M Sorensen buffer (0.1 M glycine, 0.1 M
NaCl) adjusted to pH 2.0 and in McIlvaine citrate–phos-
phate buffer (0.1 M citrate, 0.2 M disodium phosphate)
adjusted to pH values from 3.0 to 8.0, in 1.0 pH unit
intervals. H. pylori cells were re-suspended in artificial
gastric juice [17]. Co-aggregation was then assessed in a
ratio of 1:1 (DSM17648/H. pylori). pH values of final
mixtures were controlled. No pure cultures evidenced auto-
aggregation within this pH range.
Protease Pre-treatment
The strain DSM17648 and H. pylori were grown separately
to stationary phase, harvested by centrifugation, washed in
PBS, and 1 mL aliquots adjusted to A600 = 4 (for
DSM17648) or A600 = 2 (for H. pylori) in monopotassi-
um phosphate/calcium chloride buffer (pH 7.0) containing
either one of four proteases: protease Strep. griseus Type
XIV (5.7 U/mg), proteinase K (51 U/mg), trypsin (40 U/
mg) or pepsin (2,950 U/mg) at a final concentration of
2.0 mg/mL. After incubation for 1 h at 37 C, cells were
washed, re-suspended again in PBS (pH 7.0), and 500 lL
aliquots of each preparation mixed, and co-aggregation
assayed visually and microscopically.
Spray Drying and Lyophilization of Cells
Spray drying of cells was done using a Bu¨chi B-191 spray
dryer, inlet temperature 140 C, aspiration 75 % and pump
rate 5 % [20]. NaCl [75 % (w/w) final concentration] was
used as carrier substance. Before lyophilization, cells were
washed, re-suspended in 15 % (w/v) skimmed milk powder
and frozen at -80 C. Lyophilization was done under
vacuum (0, 1 mbar) for 24 h [21].
Study Population
The original setting of the study was a placebo-controlled
co-twin control design with one twin receiving the active
treatment while the co-twin received a placebo. Concor-
dance rates for H. pylori infection in monozygotic twins
have been reported at 80 % [22], whereas in dizygotic
twins they are 60 %. Heritability for quantitative levels of
H. pylori colonization has been estimated at 0.8. Historical
prevalence of infection by H. pylori for the general popu-
lation was reported as 45 %, although more recent studies
suggest a reduction to approximately 25 % in the Western
world [23, 24]. For Germany, a prevalence of 39 % was
reported in 1996 [25]. Based on those figures, the first
A
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Fig. 1 a Microscopic analysis
of co-aggregation of Lact.
reuteri DSM17648 with H.
pylori DSM21031 in artificial
stomach juice (pH 4), A H.
pylori DSM21031 stained with
hexidium iodide. B Lact. reuteri
DSM17648 stained with CFDA.
C Co-aggregate showing
clumping of both strains. Bright
field fluorescence microscopy
(OLYMPUS BX60 microscope,
100-W mercury lamp U-RFL-T,
Olympus, Japan), magnification
91000. b Co-aggregation of
Lact. reuteri DSM17648 with
H. pylori DSM21031 is
macroscopically visible. A H.
pylori DSM21031; B H. pylori
DSM21031 and Lact. reuteri
DSM17648 co-aggregates;
C Lact. reuteri DSM17648
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screening phase was planned to include analysis for 64
twin pairs, expecting 29 pairs with at least one affected
twin, and 23 concordant pairs, i.e., pairs with positive
findings for both twins. As incidence rates found in the
screening phase were lower than expected from published
figures, the original design was then adapted to include
singletons in a pre–post design. A second screening phase
included twins as well as singletons. Subjects were inclu-
ded if they had reached the age of 18 and had a positive H.
pylori finding in the 13C urea breath test (Helicobacter Test
INFAI, Dd C 4 %). Informed consent was obtained from
all persons for being included in the study. Additional
informed consent was obtained from all patients for which
identifying information is included in this article. Exclu-
sion criteria were any medication interfering with the
action of the lactobacilli, previous surgical procedures
affecting stomach or small intestine with potential inter-
ference with the study, e.g., gastrectomy or gastric bypass,
diabetes type 1 or 2, familiar lipid metabolism diseases,
any other major disease, weight changes [3 kg over the
last 3 months, pregnancy or lactation, alcohol or drug
abuse, or psychiatric diseases.
Study Protocol
The study was approved by the local ethics advisory
committee (Charite´, Berlin, Germany) and was conducted
according to the Declaration of Helsinki [26]. As the trial
was not a clinical trial, the trial was not registered, as at the
time of the trial in Germany it was not customary for pilot
type trials to be registered.
The test product (active ingredient) consisted of lyoph-
ilized dead cells of the strain DSM17648, prepared as solid
tablets for oral application. Each tablet contained 5 9 109
cells (determined by counting in Neubauer chamber), and
the daily dosage of four tablets translates into 2 9 1010
cells. Verum and placebo tablets were identical in weight
(250 mg), size, color and flavor. Within concordant
affected twin pairs, treatment was randomized in parallel
for a time period of 14 days. In singletons, active treatment
and placebo were given in a single-blinded non-random-
ized crossover design. The first period of 14 days was the
placebo phase; after a second breath test, active treatment
was given for another 14 days, followed by a breath test.
Four to six weeks after the treatment phase, a follow-up
breath test was conducted. Subjects were instructed to take
two tablets after breakfast as well as after their evening
meal. During the treatment phase, no lifestyle or dietary
changes were to be initiated and no probiotic food products
or cranberries were to be used. Subjects were asked to fill
in a study-specific questionnaire to document well-being,
any potential side effects, smoking, alcohol use, nutrition
and medication.
Measurements
Detection of H. pylori infection in the screening phase and
quantification of colonization to verify effects of the strain
DSM17648 were accomplished by a breath test, as this
diagnostic approach is best suited to screening as well as
detection of intra-individual changes [27]. Helicobacter
Test INFAI is a breath test for direct noninvasive quan-
titative detection of the bacterium H. pylori [28]. The test is
based on urease activity of H. pylori. Specificity (98.5 %)
and sensitivity (97.9 %) of Helicobacter Test INFAI are
comparable to traditional invasive diagnostic methods
(endoscopy or biopsy). As the breath test reflects the cur-
rent status of colonization by H. pylori, it is well suited to
detect reduction in or eradication of the bacteria [29, 30].
The test is based on the hydrolysis of 13C urea to
ammonium and 13C-enriched carbon dioxide, which is
detectable in the breath. Patients ingest a small amount of
the 13C urea isotope. Carbon dioxide resulting from the
degradation of urea contains this isotope, detectable by
mass spectrometry. As there is a small amount of naturally
occurring 13C even in the absence of urease activity, breath
samples are taken before and after the ingestion of 13C
urea. If there is no difference, the test is negative, indi-
cating no infection with H. pylori. There is a quantitative
relation between urease activity and amount of 13C in
breath that indirectly relates to the level of colonization by
H. pylori.
Statistics
All historical and clinical data were entered into a dedi-
cated trial database. Statistical analysis was conducted
using SPSS version 16.0.2. We computed differences in
13C urea breath test (UBT) values against initial measure-
ments: DActive = 13C UBT Active - 13C UBT Initial,
DPlacebo = 13C UBT Placebo - 13C UBT Initial, DWash-
out = 13C UBT Wash-out - 13C UBT Initial. Addition-
ally, the absolute test values between the various study
time-points were compared: 13C UBT Initial, 13C UBT
Verum (after 14-day verum treatment), 13C UBT Placebo
(after 14-day placebo treatment), 13C UBT Wash-out
(4–6 weeks after verum treatment). Data from twin pairs
were combined and analyzed as in singletons. The co-twin
control design is comparable to a crossover design, but
without any potential carry over effects. There was no
randomized order for verum/placebo treatment, as no
continuing placebo effect was expected.
All data were tested for deviations from normal distri-
bution by Kolmogorov–Smirnov test. Mean differences
were computed by pairwise t test. Potential relations
between response to treatment and initial level of coloni-
zation were explored by linear regression. An error level of
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5 % was set as threshold for significance. Results are
reported as mean ± standard deviation (SD); figures
present the standard error of the mean (SEM).
Results
Co-aggregation Analysis of Lact. reuteri DSM17648
Lactobacilli that co-aggregate H. pylori were sought among
a large Lactobacillus strain collection. The in-house, pri-
vate strain collection has been assembled from wild-type
strains of diverse origin, such as food sources, plants,
vegetables or human skin. Strains are classified according
to the physiological characteristics prior to being included
in the screening process. Among 700 Lactobacillus strains
tested, only eight were found to co-aggregate with spiral
forms of H. pylori strain DSM21031, without exhibiting
any auto-aggregation (Fig. 1). Three of the co-aggregating
lactobacilli (strains DSM17648, DSM17647 and
DSM17651) were identified as Lact. fermentum (API
method). One of these—Lact. fermentum DSM17648
[classified as Lact. reuteri by 16 S-rDNA sequencing and
sequence alignment (100 % identical to accession numbers
CP000705, CP006603, CP006011 (at 99 % coverage))]—
was analyzed in depth (Table 1). Numerous other Lact.
fermentum and Lact. reuteri strains were tested in parallel
for auto-aggregation and co-aggregation under the descri-
bed conditions. None of them formed co-aggregates with
H. pylori. Lactobacillus and Helicobacter strains did not
auto-aggregate (Fig. 1). To confirm that both species were
present in the aggregates, cells were stained separately
using either hexidium iodide or carboxyfluorescein diace-
tate succinimidyl ester. Both the strain DSM17648 and H.
pylori DSM21031 participated in the aggregation (Fig. 1).
Co-aggregation occurs within seconds after mixing the
strains. Quantification of co-aggregate formation between
Lact. reuteri DSM17648 and H. pylori DSM21031 by flow
cytometry (Fig. 2) shows that one Lactobacillus cell binds
2–3 Helicobacter cells. Interestingly, the co-aggregation
activity is preserved during lyophilization or spray drying
of whole cells of Lact. reuteri DSM17648 and persists in
non-viable cells (Table 3). Spray-dried or lyophilized cells
of strain DSM17648 induced co-aggregate formation with
the same sensitivity as untreated cells. Expression of co-
aggregation activity is dependent on the growth phase of
Lact. reuteri DSM17648, and it is present at entry into
stationary growth and during stationary phase. SEM ima-
ges of co-aggregates were prepared to analyze cellular sites
of the attachment. Figure 3 shows that single cells of the
strain DSM17648 bind several H. pylori cells resulting in
cross-linking of the co-aggregates. Binding sites on the
cells of the strain DSM17648 appear evenly distributed
over the cell surface, and binding sites on H. pylori cells do
not seem to be present on flagellar structures.
As the interaction between cells of Lact. reuteri
DSM17648 and H. pylori DSM21031 involves cell sur-
faces, we tested for possible interference by surface mod-
ulating treatments. Co-aggregation persists in the presence
of sugar (sucrose, lactose, glucose, fructose, maltose, iso-
maltose, and sorbitol). It occurs at comparable efficiency at
room temperature and at 37 C, and co-aggregation
Table 1 Aggregation of H.
pylori by lactobacilli is
Lactobacillus strain specific
a Identified by API;b identified
by 16 S rDNA sequence
Lactobacillus strain Co-aggregation
of H. pylori type
strain DSM21031T
Reference
Lact. fermentuma/reuterib
OB-LbHp-1 (DSM17648)
? This work; ORGANOBALANCE strain collection
Lact. fermentuma/reuterib
OB-LbHp-2
? This work; ORGANOBALANCE strain collection
Lact. fermentuma/reuterib
OB-LbHp-3
- This work; ORGANOBALANCE strain collection
Lact. fermentuma/reuterib
OB-LbHp-4
- This work; ORGANOBALANCE strain collection
Lact. reuterib DSM 17509 - DSMZ Braunschweig, Germany
Lact. reuteri DSM 20053 - DSMZ Braunschweig, Germany
Lact. reuteri DSM 20056 - DSMZ Braunschweig, Germany
Lact. fermentumab OB-LbHp-5 - This work; ORGANOBALANCE strain collection
Lact. fermentumab OB-LbHp-6 - This work; ORGANOBALANCE strain collection
Lact. fermentumab OB-LbHp-7 - This work; ORGANOBALANCE strain collection
Lact. fermentumab OB-LbHp-8 ? This work; ORGANOBALANCE strain collection
Lact. fermentumab OB-LbHp-9 ? This work; ORGANOBALANCE strain collection
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Fig. 2 Co-aggregation of Lact. reuteri DSM17648 with H. pylori
DSM21031 was analyzed by flow cytometry (e). H. pylori cells were
CFDA stained. Samples were analyzed using flow cytometry, and cell
co-aggregation was quantified by determining the events with a high
FL ([5 9 102, area within green frame). Co-aggregation was not
observed when strains were analyzed separately (a–c) nor when a
non-aggregating Lactobacillus strain was used as a control (d)
Fig. 3 Scanning electron microscopy of co-aggregates of Lact. reuteri DSM17648 (blue) and H. pylori (red), a 91,800 magnification;
b 911,000 magnification. Some images were colorized according to the bacillary or spiral shape to facilitate viewing
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activity is observed over a wide pH range (pH 2.0—cor-
responding to empty stomach conditions—up to pH 8,
including typical pH values after meals). No pure cultures
evidenced auto-aggregation within this pH range. Slightly
smaller co-aggregates formed at pH 2 compared with pH 8
in vitro. Thus, aggregation of H. pylori by Lact. reuteri
DSM17648 occurs at pH values and conditions encoun-
tered in the human stomach.
The susceptibility to protease inactivation of the co-
aggregation determinants on the surfaces of both the strain
DSM17648 and H. pylori DSM21031 was tested after
treatment with protease Strep. griseus Type XIV, protein-
ase K, trypsin or pepsin. Incubating Lact. reuteri
DSM17648 with any protease before co-aggregation
reduced binding to H. pylori DSM21031 by 30 %, but did
not eliminate it completely. H. pylori required pretreatment
with the protease pepsin (as is naturally present in gastric
fluids) to be fully active in co-aggregation with the strain
DSM17648.
Lactobacillus reuteri DSM17648 does not co-aggregate
with common non-Helicobacter members of the human
flora. Neither the major intestinal commensals nor C. jejuni
detectably co-aggregate with Lact. reuteri DSM17648
(Table 2), and no auto-aggregation was observed. Co-
aggregation is active with different H. pylori strains (type I
and type II strains) as well as with H. heilmannii strains
(type I and type II) and with H. canis of animal source.
Thus, the strain DSM17648 specifically co-aggregates H.
pylori without interfering with other bacteria of the com-
mensal intestinal flora.
Pilot Study
The strain DSM17648 was used in a placebo-controlled pilot
study to evaluate the effect of the strain DSM17648 in
asymptomatic Helicobacter-positive test persons after a two-
week application. Screening included 128 subjects, 47 twin
pairs and 34 singletons; 27 subjects had a positive breath test
result. OverallHelicobacter prevalence was 21 %; 6 twin pairs
were concordant and 10 pairs discordant positive. Fourteen
independent treatments were started with no dropouts during
the trial phase. All 6 concordant twin pairs participated in the
study, as well as 4 discordant twin pairs and 4 singletons. Due to
the large inter-individual variability of quantitative measures of
colonization (13C UBT Initial), analysis of H. pylori reduction
by the strain DSM17648 was primarily based on intra-indi-
vidual changes after active treatment or placebo (Dverum vs.
Dplacebo). Treatment by placebo did not result in a significant
change in 13C UBT (Dplacebo -0.6 ± 5.3), whereas verum
treatment significantly reduced 13C UBT values (Dverum
-4.9 ± 7.8, p = 0.026 vs. placebo), indicating significant
reduction in H. pylori. Absolute values of 13C UBT at baseline
measurement, after placebo and after verum treatment were
14.1 ± 9.9, 12.7 ± 7.2 (ns vs. initial) and 11.9 ± 5.9 (p vs.
initial 0.01, p vs. placebo 0.03), respectively. To allow for a
detailed evaluation of response to the strain DSM17648, indi-
vidual values for 13C UBT are plotted in Fig. 4. After verum
treatment, the majority of subjects showed a reduction in H.
pylori colonization. Responses showed some variability, from
no reduction to a delta of more than 20. In comparison, after
2 weeks of placebo, some subjects had lowered values while
others had increases in the same magnitude, indicating no
systematic effect.
Values of 13C UBT after wash-out (x ± y) are not signifi-
cantly different from verum treatment values. The effect of
reduced Helicobacter values lasts over the actual treatment.
There was some dependency of treatment response on initial
values (r2 = 0.66, p = 0.01, Fig. 5). With increasing level of
colonization, the lowering effect caused by the strain
DSM17648 becomes stronger. For placebo treatment, the same
dependency was found albeit to a lesser degree (r2 = 0.35,
p = 0.02), probably reflecting regression to the mean effects. A
direct placebo effect on immune response cannot be ruled out.
This potential effect is significantly lower than the specific
action of the strain DSM17648. During the course of the study,
there was neither any change in life style, e.g., in physical
activities or diet, nor health as indicated by the questionnaire.
No side effects were reported in either study group.
Discussion
The specific and fast co-aggregation of defined Lactoba-
cillus strains of the species Lact. reuteri/fermentum, Lact.
Table 2 Lact. reuteri strain DSM17648 co-aggregates different types
and species of Helicobacter, but not Campylobacter and bacterial
representatives of oral or intestinal flora
Strains Co-aggregation by
Lact. reuteri DSM 17648
H. pylori DSM 9691, type I ?
H. pylori DSM 10242, type I ?
H. pylori DSM 21031T, type I ?
H. pylori CCUG 19106, type II ?
H. heilmannii ATCC 49286, type 1 ?
H. heilmannii DSM 24751T, type 2 ?
H. canis CCUG 32756 ?
Campylobacter jejuni DSM 4688T -
Streptococcus salivarius DSM 20560T -
Clostridium leptum DSM 753T -
Clostridium saccharolyticum DSM 2544T -
Bacteroides fragilis DSM 2151T -
Escherichia coli DSM 30083T -
T Type strains
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brevis and Lact. pentosus (typified Lact. reuteri
DSM17648) with H. pylori under gastric conditions is
novel. Co-aggregation of Lact. reuteri DSM17648 also
occurs with H. heilmannii and H. canis. Major commensals
in the intestinal environment are not co-aggregated by
Lact. reuteri DSM17648. Numerous other lactobacilli in a
very large collection of Lactobacillus wild-type strains
(collected from various natural habitats) including many
other Lact. fermentum, Lact. brevis and Lact. pentosus
strains fail to manifest H. pylori-specific co-aggregation.
Co-aggregation activity is not affected by sugars and pH
(over a wide range between 2 and 8), and it requires a
pepsin pretreatment of spiral form cells of H. pylori. It does
not occur with far less infective coccoidal H. pylori cells
[31], and it is dependent on a Lact. reuteri DSM17648 cell
surface factor that is present at the end of the exponential
growth phase and during stationary phase. Co-aggregation
between H. pylori and the strain DSM17648 occurs within
seconds. While Chen et al. [32] observed a very slow
interaction between some lactobacilli from food source, the
present paper is to our knowledge the first description of a
rapid and efficient co-aggregation of H. pylori by a specific
Lactobacillus strain under gastric conditions. It is proposed
that Lact. reuteri DSM17648 interferes with mobility of H.
pylori and its adherence to the gastric mucosa by entan-
gling the cells into aggregates and masking H. pylori sur-
face sites that are ordinarily available for binding to human
epithelium. Once bound, co-aggregates will be flushed
from the stomach by natural bowel movement. Interest-
ingly, the aggregation activity was preserved when the cells
were killed by freeze drying or spray drying. It can be
assumed that binding is due to specific surface molecules
on the Lact. reuteri DSM17648 cells which are strain
specific and are resistant to such process steps. Such sur-
face molecules might include lipoteichoic acid and carbo-
hydrate structures.
This novel anti-H. pylori activity has not been described
previously as a mode of action for probiotic treatment of H.
pylori infections. This hypothesis was tested in a proof-of-
concept in vivo study. Our data demonstrate the significant
decrease in H. pylori load by a two-week application of
Fig. 4 Absolute 13C UBT
values of individuals before and
after treatment with verum and
placebo
Fig. 5 Linear regression between initial values and response to
treatment (verum). Response is significantly stronger with increased
basal H. pylori colonization level
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Lact. reuteri DSM17648 in healthy subjects with detect-
able H. pylori infection in a general population sample. The
principal outcome criterion was the reduction in H. pylori
as measured by 13C urease breath test (Helicobacter Test
INFAI) after a 14-day supplementation period of Lact.
reuteri DSM17648 at a daily dose of 2 9 1010 non-viable
lyophilized cells. Data obtained in a parallel clinical study
support the data reported in this paper [33]. Previous
studies with non-specific probiotics require the application
of live microorganisms while Lact. reuteri DSM17648 is
active as non-viable cell preparation. This will greatly
reduce any potential side effects and will help ensure stable
activity in a potential consumer product and in pharma-
ceutical and medicinal formulations.
Our study reveals a novel Lact. reuteri strain (the strain
DSM17648) that features unique properties as it specifi-
cally aggregates with planktonic H. pylori in the stomach.
Freeze-dried (and spray-dried) preparations significantly
reduce the H. pylori load (measured by urease breath test)
after a 14-day oral treatment period in H. pylori-positive
test persons.
Lact. reuteri strain DSM17648 can become a central
part of a strategy to avoid using antibiotics and combating
antibiotic resistances in H. pylori infections, in reducing H.
pylori load, either as a prophylactic food additive or a
medical cure to treat H. pylori-induced stomach diseases.
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